Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 24, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5910

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 85–96 of 5,910 matching trials for Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
Interventions: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: ABBV-1480, Pembrolizumab, Carboplatin, Paclitaxel, Nab- Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Brain Metastases, Breast Cancer, Lung Cancer, Leptomeningeal Disease, LMD
Interventions: QBS72S; Drug
Lead sponsor: Melanie Hayden Gephart; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Osimertinib, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • New Haven, Connecticut

Conditions: Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer
Interventions: PCNA Inhibitor AOH1996; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Duarte, California • Long Beach, California

Conditions: Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions: obrixtamig, atezolizumab, carboplatin, etoposide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Mobile, Alabama • Little Rock, Arkansas • Hialeah, Florida + 14 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Setidegrasib, Docetaxel; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Glendale, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
Interventions: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E); Drug
Lead sponsor: Immuneering Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 20
States / cities: Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more

Conditions: Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Placebo, Pembrolizumab; Drug · Other · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 15
States / cities: Bakersfield, California • Beverly Hills, California • Stamford, Connecticut + 12 more

Conditions: Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions: Immunotherapy CARE Program; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

Study Assessing QBS72S For Treating Brain Metastases

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma

AOH1996 for the Treatment of Refractory Solid Tumors

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

About this Lung Cancer clinical trials directory page